Insights Into Renal Cell Carcinoma (RCC)
Perspectives on drivers in treatment decisions in the management of RCC
Great Plains/Central/Midwest – March 14, 2024
Faculty Chair
Manojkumar Bupathi, MD
Rocky Mountain Cancer Centers, Littleton, CO, USA
Mid-Atlantic – April 24, 2024
Faculty Chair
Yasser Ged, MBBS
Johns Hopkins Hospital, Baltimore, MD, USA
Northwest – June 22, 2024
Faculty Chair
Manojkumar Bupathi, MD
Rocky Mountain Cancer Centers, Littleton, CO, USA
Southwest – September 30, 2024
Alexandra Drakaki, MD, PhD
University of California, San Francisco, CA, USA
More Information
- Virtual Series
More Information
- Virtual series
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Virtual series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
More Information
- Virtual series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of RCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
